

24.05.18

ASX ANNOUNCEMENT

ASX Market Announcements Australian Securities Exchange Limited 10th Floor, 20 Bond Street SYDNEY NSW 2000

RE-APPOINTMENT OF EXECUTIVE DIRECTOR - CATHERINE COSTELLO

Admedus Limited (ASX:AHZ) (the **Company**) announces the re-appointment of Catherine Costello as interim Executive Director.

On 23 May 2018 Ms Costello was appointed interim Executive Director following the resignation of Mr Mathew Ratty to ensure the Company complied with the requirement to have a minimum of two resident Australian Directors. As Ms Costello was an interim appointment by the board, the Company's constitution required that she cease to be a director following the Company's Annual General Meeting and then be immediately reappointed by the board.

Ms Costello also holds the dual roles of Chief Financial Officer and Company Secretary. In her capacity in both of those roles she is immersed in the operations and strategy of the business and is a senior leader within the Company.

Ms Costello brings more than 20 years of experience in Australian and multinational businesses, including large ASX-listed and US-listed entities, in key management roles responsible for financial management and governance. She has been closely involved in strategic decision making and transformative business and organisational structuring processes, and strong cost management.

Ms Costello is a graduate of both the Australian Institute of Company Directors and the Governance Institute of Australia. She has a Bachelor of Commerce from the University of Queensland, a Masters of Science from Curtin University, and is a Chartered Accountant, and Chartered Secretary. She also serves on a number of community based committees.



Summary of key terms of continued employment:

As outlined in the Remuneration Report (July-December 2017)

Appointment: The appointment is to the position of Executive Director of Admedus Limited.

Term: Ongoing, no fixed term. Notice period of six months by either party.

Remuneration:

- Total Fixed Remuneration: Ms Costello will be paid a fixed cash remuneration in the form of a Total Fixed Remuneration (TFR) package (inclusive of superannuation and allowances) subject to annual review. Her TFR is \$370,653.
- Short Term Incentive: Ms Costello will be entitled to a potential maximum short-term incentive of 32.25% of her base salary per annum. Payout of any performance bonus is at the discretion of the Board and meeting performance targets and priorities set by the Board in consultation with Ms Costello.
- Long Term Incentive: Ms Costello will be entitled to participate in the Admedus Limited executive long-term incentive scheme in accordance with the rules of the schemes and any applicable Admedus policy. Ms Costello will be entitled to a total long-term incentive grant.

ENDS

About Admedus Limited

Admedus (ASX:AHZ) is a medical technologies company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Website: www.admedus.com

Facebook: www.facebook.com/Admedus

Twitter: @Admedus

For more information, please contact:

Admedus Limited

Barbara Ferres

+61 7 3152 3216

communications@admedus.com

Admedus Limited ABN 35 088 221 078

Registered Office Level 9

301 Coronation Drive Milton QLD 4064 Customer Service T 1300 550 310 F 1300 880 398

International

T: +61 8 9266 0100 F: +61 8 9266 0199 E: info@admedus.com W: www.admedus.com

Brisbane • Minneapolis
Zurich • Singapore